NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IBIII ALK plus NSCLC

被引：0
|
作者：
Lee, J. M. [1 ]
Toloza, E. M. [2 ,3 ]
Pass, H. I. [4 ]
Johnson, B. E. [5 ]
Heymach, J. V. [6 ]
Sholl, L. [7 ]
Saqi, A. [8 ]
Travis, W. D. [9 ]
Wistuba, I. [6 ]
Lin, J. [10 ]
Kris, M. G. [9 ]
Spira, A. I. [11 ,12 ]
Shu, C. A. [8 ]
Saltos, A. N. [13 ]
Ding, B. [14 ]
Schulze, K. [14 ]
Zhu, Q. [14 ]
Ngiam, C. [14 ]
Bara, I. [14 ]
Chaft, J. E. [9 ]
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Univ South Florida Hlth, Morsani Coll Med, Tampa, FL USA
[4] NYU Langone Med Ctr, New York, NY USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] MD Anderson Canc Ctr, Houston, TX USA
[7] Brigham & Womens Hosp, Boston, MA USA
[8] Columbia Univ, Med Ctr, New York, NY USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Univ Michigan, Med Sch, Ann Arbor, MI USA
[11] US Oncol Res, The Woodlands, TX USA
[12] Virginia Canc Specialists, Fairfax, VA USA
[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[14] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
alectinib; neoadjuvant; local-regional NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-06
引用
收藏
页码：S297 / S298
页数：2
相关论文
共 50 条
  • [31] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice
    Weiss, Glen J.
    Dorer, David J.
    Rivera, Victor M.
    Conlan, Maureen G.
    Kerstein, David
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239
  • [32] Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC
    Mok, T. S. K.
    Shaw, A. T.
    Camidge, R. D.
    Gadgeel, S. M.
    Rosell, R.
    Dziadziuszko, R.
    Kim, D-W.
    Perol, M.
    Ou, S-H.
    Bordogna, W.
    Smoljanovic, V.
    Hilton, M.
    Peters, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 607 - 607
  • [33] A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with ALK plus NSCLC
    Shaw, Alice
    Loong, Herbert
    Tan, Daniel S. -W.
    Griscti, Kerry
    Gao, Haitao
    Finckenstein, Friedrich
    Scott, Jeffrey
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S430 - S430
  • [34] The Safety Profile and Preliminary Efficacy of Ceritinib 450mg with Food in Chinese ALK/ROS-1 Positive NSCLC Patients
    Tian, Y.
    Yu, P.
    Yin, X.
    Wang, K.
    Huang, M.
    Wang, Y.
    Gong, Y.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S935 - S936
  • [35] Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute
    Akazawa, Y.
    Yoshikawa, A.
    Hashimoto, K.
    Ishijima, M.
    Kanazu, M.
    Yano, Y.
    Mori, M.
    Yamaguchi, T.
    Uchida, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S486 - S486
  • [36] Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC in the ALTA-1L and J-ALTA studies
    Camidge, D. Ross
    Sugawara, Shunichi
    Kondo, Masashi
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Kudou, Kentarou
    Asato, Takayuki
    Liu, Yuyin
    Vranceanu, Florin
    Fram, Robert J.
    Ohe, Yuichiro
    Popat, Sanjay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
    Gettinger, S.
    Bazhenova, L.
    Salgia, R.
    Langer, C.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC
    Mazieres, J.
    Novello, S.
    De Castro, J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    Wolf, J.
    Zeaiter, A.
    Cardona, A.
    Balas, B.
    Karagiannis, T.
    Chlistalla, M.
    Smoljanovic, V.
    Oh, I.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1897 - S1897
  • [39] Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC.
    Peters, Solange
    Mok, Tony S. K.
    Gadgeel, Shirish M.
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong Ignatius
    Shaw, Alice Tsang
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Ruf, Thorsten
    Archer, Venice Rosale
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
12345